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ABSTRACT: 
Background and aims: The effect of statin therapy on plasma adiponectin levels has not been 
conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review 
and meta-analysis of available randomized controlled trials (RCTs). 
Methods: Quantitative data synthesis was performed using a random-effects model with 
weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.  
Results: In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma 
adiponectin levels was observed after statin therapy (WMD: 0.57 µg/mL, 95% CI: 0.18, 0.95, 
p=0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and 
pitavastatin were found to change plasma adiponectin concentrations by 0.70 µg/mL (95% CI: -
0.26, 1.65), 0.50 µg/mL (95% CI: -0.44, 1.45), -0.70 µg/mL (95% CI: -1.08, -0.33), 0.62 µg/mL 
(95% CI: -0.12, 1.35), and 0.51 µg/mL (95% CI: 0.30, 0.72), respectively. With respect to 
duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks 
(WMD: 0.88 µg/mL, 95% CI: 0.19, 1.57, p=0.012) but not in the subset of <12 weeks of 
duration (WMD: 0.18 µg/mL, 95% CI: -0.23, 0.58, p=0.390). Random-effects meta-regression 
suggested a significant association between statin-induced elevation of plasma adiponectin and 
changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; 
p=0.002).  
Conclusions: The meta-analysis showed a significant increase in plasma adiponectin levels 
following statin therapy. Although statins are known to increase the risk for new onset diabetes 
mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction 
in adiponectin expression.  
 
Keywords: adiponectin, statins, hydroxymethylglutaryl-CoA reductase inhibitors, meta-analysis. 
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INTRODUCTION 
Adiponectin is an adipocyte-derived plasma protein secreted mainly by white adipose tissue 1. 
It impacts metabolism of carbohydrates and fatty acids in the liver cells and muscles, indirectly 
influencing the insulin resistance via decreasing hepatic gluconeogenesis, increasing glucose 
uptake and beta-oxidation in the muscles 2. In the circulation, adiponectin exists in three oligomeric 
forms: a low-molecular weight trimer, a medium molecular weight hexamer and a larger High–
Molecular Weight (HMW) adiponectin form 3. The HMW adiponectin is in particular the major 
active form of protein, which is primarily associated with insulin resistance and the presence of 
metabolic syndrome 4. The adiponectin gene (ADIPOQ) located at position 3q27 is considered 
the most important genetic factor regulating plasma adiponectin levels 5. The levels of plasma 
adiponectin are higher in women than in men and vary by ethnicity, being lower in African-
Americans than in Caucasians 6, 7. Several single nucleotide polymorphism (SNPs) of the 
adiponectin gene such as SNP45, SNP276, SNP11377 and SNP11391 were associated with low 
plasma concentrations of adiponectin and type 2 diabetes mellitus (DM) 8. Moreover, a sedentary 
life and high fat diet seems to be associated with disturbances of plasma adiponectin 
concentrations 9. Indeed, it has been recently shown that obesity induces a DNA 
hypermethylation of ADIPOQ gene 10. Low plasma concentrations of adiponectin have been 
observed in patients with metabolic syndrome, DM, obesity, hypertension, and coronary artery 
disease (CAD) 11-14. Nevertheless, increased plasma levels of adiponectin have been found to be 
associated with increased values of C-reactive protein (CRP), interleukin-6 (IL-6), and tumor 
necrosis factor-alpha (TNF-α), suggesting a role of adiponectin in inflammatory processes 15. 
Adiponectin also stimulates endothelial production of nitric oxide (NO) and endothelin-1 (ET-1), 
inhibits monocyte adhesion to endothelial cells and macrophage-derived foam cell transformation, 
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simulates angiogenesis through promotion of cross-talk between Akt signaling and AMP-
activated protein kinase and attenuates TNF-α-induced expression of adhesion molecules in 
endothelial cells 16. Plasma adiponectin levels were negatively correlated with triglyceride and 
low-density lipoprotein cholesterol (LDL-C), but positively correlated with high-density 
lipoprotein cholesterol (HDL-C) levels in clinical trials 17, 18. Similarly to HDL-C its level increases 
after physical exertion 19.  
Statins have been shown to have pleiotropic effects, influencing endothelial function, platelet 
adhesion, thrombosis, plaque stability, and inflammation, however there have been recently a 
discussion whether this effect is not only related to potent LDL-C reduction 20, 21. Available data 
also suggest that statins may have an impact on the adiponectin levels and hence the use of statins 
should be recorded, as can be a potential confounder. On the other hand statin therapy increases 
the risk of new onset diabetes (NOD), and one of the investigated hypotheses of this mechanism 
might be adipokines related 22.  
Taking into account that statin therapy might modulate plasma adiponectin concentrations, and 
the exact effects are not completely known, we evaluated the impact of statin therapy on plasma 
adiponectin concentrations in the systematic review and meta-analysis of randomized controlled 
trials (RCTs).  
 
Materials and methods 
The analysis was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement 23. Due to the study design (meta-
analysis of randomized controlled trials) no Institutional Review Board (IRB) approval, as well 
as no patients’ informed consents was obtained.   
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Search strategy 
The analysis was designed according to the guidelines of the 2009 preferred reporting items 
for systematic reviews and meta-analysis (PRISMA) statement 23. PubMed, Medline and SCOPUS 
databases were searched using the following search terms in titles and abstracts: (atorvastatin OR 
simvastatin OR rosuvastatin OR fluvastatin OR pravastatin OR pitavastatin OR lovastatin OR 
cerivastatin OR) AND (adiponectin). Additional searches for potential trials included the 
references of review articles on that issue, and the abstracts from selected congresses: scientific 
sessions of the European Society of Cardiology (ESC), the American Heart Association (AHA), 
the American College of Cardiology (ACC), European Society of Atherosclerosis (EAS) and 
National Lipid Association (NLA). The wild-card term ‘‘*’’ was used to increase the sensitivity of 
the search strategy. All searches were limited to studies in human. The literature was searched 
from inception to March 1, 2015. Two reviewers (CS and AS) examined every article separately 
to minimize the possibility of duplication, investigating reviews, case studies and experimental 
studies. Disagreements were resolved by discussion with a third party (MB). 
 
Study selection 
Original studies were included if they met the following inclusion criteria: (i) having a 
randomized controlled design in either parallel or cross-over form, (ii) investigating the impact of 
statin therapy (in monotherapy or in the combined therapy) on plasma/serum concentrations of 
adiponectin, (iii) treatment duration of at least two weeks, (iv) presentation of sufficient 
information on plasma/serum adiponectin concentrations at baseline and at the end of follow-up in 
each group or providing the net change values.  
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Exclusion criteria were (i) non-clinical studies, (ii) lack of a control group in the study design, 
(iii) observational studies with case-control, cross-sectional or cohort design, and (iv) lack of 
sufficient information on baseline or follow-up adiponectin concentrations.  
   
Data extraction  
Eligible studies were reviewed and the following data were abstracted: 1) first author's name; 
2) year of publication; 3) study location; 4) study design; 5) number of participants in the statin and 
control groups; 5) type, dose and duration of statin therapy; 6) age, gender and body mass index 
(BMI) of study participants; 7) baseline levels of total cholesterol, LDL-C, HDL-C, triglycerides, 
hs-CRP and glucose; 8) systolic and diastolic blood pressures; and 9) data regarding baseline and 
follow-up concentrations of adiponectin. Data extraction was performed independently by 2 
reviewers; disagreements were resolved by a third reviewer. 
 
Quality assessment 
A systematic assessment of bias in the included studies was performed using the Cochrane 
criteria 24. The items used for the assessment of each study were as follows: adequacy of sequence 
generation, allocation concealment, blinding of subjects and personnel, blinding of outcome 
assessment, addressing of dropouts (incomplete outcome data), selective outcome reporting, and 
other potential sources of bias. According to the recommendations of the Cochrane Handbook, a 
judgment of “yes” indicated low risk of bias, while “no” indicated high risk of bias. Labeling an 
item as “unclear” indicated an unclear or unknown risk of bias. Risk-of-bias assessment was 
performed independently by 2 reviewers; disagreements were resolved by a third reviewer. 
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Quantitative data synthesis 
Meta-analysis was conducted using Comprehensive Meta-Analysis (CMA) V2 software 
(Biostat, NJ) 25. Net changes in measurements (change scores) were calculated as follows: measure 
at end of follow-up − measure at baseline. For single-arm cross-over trials, net change in plasma 
concentrations of adiponectin were calculated by subtracting the value after control intervention 
from that reported after treatment. Standard deviations (SDs) of the mean difference were 
calculated using the following formula: SD = square root [(SDpre-treatment)2 + (SDpost-treatment)2 – (2R × 
SDpre-treatment × SDpost-treatment)], assuming a correlation coefficient (R) = 0.5. If the outcome 
measures were reported in median and inter-quartile range, mean and standard SD values were 
estimated using the method described by Hozo et al. 26. To convert interquartile range into Min-
Max range, the following equations were used: A = median + 2 × (Q3 – median) and B = median – 
2 × (median – Q1), where A, B, Q1 and Q3 are upper and lower ends of the range, upper and lower 
ends of the interquartile range, respectively. Where standard error of the mean (SEM) was only 
reported, standard deviation (SD) was estimated using the following formula: SD = SEM × sqrt 
(n), where n is the number of subjects. In case the values were only presented as graph, the 
software GetData Graph Digitizer 2.24 (http://getdata-graph-digitizer.com/) was applied to digitize 
and extract the data. 
A random-effects model (using DerSimonian-Laird method) and the generic inverse variance 
method were used to compensate for the heterogeneity of studies in terms of demographic 
characteristics of populations being studied and also differences in study design and type of statin 
being studied 27. Heterogeneity was quantitatively assessed using I2 index. Effect sizes were 
expressed as weighted mean difference (WMD) and 95% confidence interval (CI). Sensitivity 
analysis was performed using leave-one-out method. In this method, each study is iteratively 
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removed at a time to confirm that the pooled estimate of effect size is not driven by any single 
study.  
 
Meta-regression 
Random-effects meta-regression was performed using unrestricted maximum likelihood 
method to evaluate the association between calculated WMD and duration of statin therapy and 
changes in plasma LDL-C concentrations as potential moderator variables. 
 
 
Publication bias 
Potential publication bias was explored using visual inspection of Begg’s funnel plot 
asymmetry, classic “fail-safe N” methods and Begg’s rank correlation and Egger’s weighted 
regression tests. Duval & Tweedie “trim and fill” method was used to adjust the analysis for the 
effects of publication bias 28. 
 
RESULTS 
Search results and trial flow 
The initial screening for potential relevance removed the articles with titles and/or abstracts 
that were obviously irrelevant. Among the 47 full text articles assessed for eligibility, 17 studies 
were excluded because: uncontrolled design (n=2), not appropriately controlled for statin therapy 
(n=5), not measuring adiponectin concentrations (n=1), non-random design (n=3), non-
interventional design (n=3), short (<2 weeks) duration of treatment (n=1), incomplete data (n=1), 
non-clinical study (n=1) (Fig. 1). After final assessment, 30 trials with 43 treatment arms achieved 
the inclusion criteria and were preferred for the final meta-analysis.  
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In total, 1470 participants were allocated to statin therapy groups, 482 to combined therapy 
groups and 1001 to control groups in the 30 selected studies. The number of participants in these 
trials ranged from 30 to 217. Included studies were published between 2004 and 2014, and were 
conducted in Korea (n=12), Japan (n=5), USA (n=3), Poland (n=2), Germany (n=2), Italy, 
Taiwan, Lebanon, Egypt, China, and the Netherlands. The following statin doses were 
administered in the included trials: 10 mg to 40 mg/day simvastatin, 10 mg to 80 mg/day 
atorvastatin, 10 mg to 40 mg/day pravastatin, 2.5 mg to 10 mg/day rosuvastatin, and 2 mg/day 
pitavastatin. Combined therapy was administered in 11 trials (statins plus fibrates or pioglitazone 
or ezetimibe or amlodipine or ramipril or sartans or eicosapentaenoic acid). Duration of statin 
intervention ranged between 14 days and 12 months. 25 trials were designed as parallel group 
and 5 as crossover studies. All studies employed immunoassay methods for the quantification of 
adiponectin levels. 
Two studies were multicenter. Demographic and baseline parameters of the included trials 
are shown in Table 1. 
 
Risk of bias assessment 
Some of the included studies were characterized by lack of information about the random 
sequence generation and allocation concealment. Details of the quality assessment are shown in 
Table 2. 
 
Effect of statin therapy on plasma adiponectin concentrations 
Changes in plasma adiponectin concentrations following statin therapy were reported in 43 
treatment arms. A significant increase in plasma adiponectin concentrations was observed 
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following statin therapy (WMD: 0.57 µg/mL, 95% CI: 0.18, 0.95, p = 0.004) (Fig. 2). This effect 
was robust in the sensitivity analysis (Fig. 3). In the subgroup analysis, atorvastatin, simvastatin, 
rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations 
by 0.70 µg/mL (95% CI: -0.26, 1.65, p = 0.152), 0.50 µg/mL (95% CI: -0.44, 1.45, p = 0.297), -
0.70 µg/mL (95% CI: -1.08, -0.33, p = 0.001), 0.62 µg/mL (95% CI: -0.12, 1.35,              p = 
0.100), and 0.51 µg/mL (95% CI: 0.30, 0.72, p = 0.001), respectively (Figure 4). With respect to 
duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks 
(WMD: 0.88 µg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset with <12 weeks of 
duration (WMD: 0.18 µg/mL, 95% CI: -0.23, 0.58, p = 0.390) (Fig. 5). There was a greater effect 
in the subset of trials in which statins were administered as monotherapy (WMD: 0.70 µg/mL, 
95% CI: 0.02, 1.39, p = 0.044) versus the subset that used a combination therapy approach (WMD: 
0.11 µg/mL, 95% CI: -0.31, 0.54, p = 0.599) (Fig. 6). With respect to diabetes, there was a 
significant increase in plasma adiponectin concentrations in the subsets of trials without diabetes as 
an inclusion criterion (WMD: 0.62 µg/mL, 95% CI: 0.15, 1.08, p = 0.010), and not in the subset of 
trials defining diabetes as an inclusion criterion (WMD: 0.34 µg/mL, 95% CI: -0.41, 1.09, p = 
0.373).  
 
Meta-regression 
Random-effects meta-regression suggested a significant association between statin-induced 
elevation of plasma adiponectin concentrations and changes in plasma LDL-C levels (slope: 0.04; 
95% CI: 0.01, 0.06; p = 0.002) (Fig. 7). However, changes in plasma adiponectin concentrations 
were not found to be associated with treatment duration (slope: -0.01; 95% CI: -0.05, 0.04; p = 
0.816) (Fig. 7). 
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Publication bias 
The funnel plot of the study precision (inverse standard error) by effect size (WMD) was 
asymmetric and suggested potential publication bias. This asymmetry was addressed by imputing 
nine potentially missing studies on the right side of funnel plot using “trim and fill” correction 
(Fig. 8). The imputed effect size was 0.87 µg/mL (95% CI: 0.41, 1.32). There was no sign of 
publication bias according to the results of Begg’s rank correlation (Kendall’s Tau with continuity 
correction = -0.001, z = 0.01, two-tailed p-value = 0.992) and Egger’s linear regression (intercept = 
0.83, standard error = 0.50; 95% CI = -0.19, 1.84, t = 1.64, df = 41, two-tailed p = 0.109) tests. The 
“fail safe N” method indicated that 124 theoretically missing studies would be required to make the 
overall estimated effect size non-significant.  
 
DISCUSSION 
To our best knowledge, the present study is the first meta-analysis to comprehensively 
assess the association between statin therapy and plasma adiponectin concentrations. The results 
showed that statins significantly increase, irrespective of the medication dose, the plasma 
adiponectin concentrations, especially in the subset of trials lasting ≥12 weeks, but not in the subset 
with <12 weeks of duration. This effect was even greater in the subset of trials in which statins 
were administered as monotherapy compared with the subset that used a combination therapy. It is 
especially interesting as the studies included in this meta-analysis combined statins with various 
drugs, which can directly or indirectly stimulate PPAR alfa (e.g. fenofibrate) 29 or PPAR gamma 
receptors (e.g. eicosapentaenoic acid, pioglitazone, ramipril) 30, and consequently increase the 
expression of adiponectin receptors in macrophages and increase plasma adiponectin 
concentrations in monotherapy.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
This meta-analysis confirmed that statins may have an important impact on the adiponectin 
levels and hence the use of statins (in monotherapy or in the combination therapy) should be 
recorded, as can be a potential confounder. This analysis supports the results of our previous 
meta-analyses, in which we confirmed that statins have important out-of-lipid lowering 
properties, which might explain, at least in part, the potent effectiveness of these drugs in 
reducing cardiovascular risk 20, 21, 31, 32. The mechanism why statin therapy produces an increase 
of plasma adiponectin concentrations seems not to be related to a reduction in adiponectin 
expression of these tissue-derived proteins 33. Many available trials described the increased risk 
for NOD after statin therapy, addressing this complication as a possible side effect 34. A meta-
analysis of 6 trials comprising 57,593 patients showed a 13% higher NOD incidence in statin users 
compared to non-users 35. Several mechanisms were described in NOD with statins, such as the 
modification of intracellular signal transduction pathways of insulin caused by inhibition of 
phosphorylation and inhibition of β-cell proliferation 36, differences in lipophilicity, inhibition of 
3-hydroxy-3-methylglutaryl coenzyme A reductase activity, decrease of mevalonate synthesis, 
inhibition of isoprenoid biosynthesis, decrease of peroxisome proliferator activated receptor 
gamma (PPAR-γ) and inhibition of adipocytes differentiation 37. Nevertheless, the reduction of 
the action of small GTPase prevents proper transmission of the signals in pancreatic cells 38, 39. 
The secretion of insulin in statin-related NOD might be decreased through reduction of the ATP in 
the mitochondria of pancreatic cells, determined by reduced concentration of coenzyme Q10 40, 41. 
The decrease of glucose uptake by adipocytes seems to be a consequence of the reduction of 
glucose protein transporter type 4 (GLUT-4) on their surface 42, 43, while the generation of non-
specific inflammation conditions in pancreatic cells is a result of increased compensating uptake of 
oxidized LDL particles 44 with consecutively decrease of plasma adiponectin concentrations. Some 
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studies have shown the effects of statins on the level of secretion of adipokines; thus changing 
the secretory profile of adipose tissue might be another mechanism by which statins increase risk 
for DM 22. However, the authors aware that there is still no convincing evidence that lower 
adiponectin levels are causally associated with diabetes, and the obtained results cannot explain 
the increase in diabetes risk in statin users, because this cannot be answered within the meta-
analysis.  
The association between statin therapy and adiponectin levels vary upon statin type and dose 
47-50
. The results of our meta-analysis showed that both atorvastatin and pravastatin were more 
effective (numerically) than other statins in increasing plasma adiponectin concentrations. In 
contrast, rosuvastatin decreased plasma adiponectin concentrations. The main difference between 
strong hypolipemiant properties of rosuvastatin and the rest of statins is the increased affinity for 
hepatocytes with low systemic bioavailability 45, 46 and consecutive lower effect on adiponectin 
secretion 47. By all the statins, only pitavastatin did not show pro-diabetes effects in clinical trials 
48
, what might be in the line with the results of the meta-analysis, and significant increase of 
adiponectin concentrations after pitavastatin therapy observed.  
The available studies have emphasized primarily a clear correlation between adiponectin 
concentration and HDL-C and inverse correlation between adiponectin concentration and 
concentration of triglycerides 9, while the relationship between adiponectin and LDL-cholesterol 
levels is unclear. Interestingly, the results of the meta-analysis also confirm the relationship 
between plasma adiponectin concentration after statins and LDL-C levels. 
Our meta-analysis has noteworthy limitations. The studies included had a relatively small 
population size and were heterogeneous, regarding the characteristics of patients and study 
design - inclusion criteria, statin dose and duration of the therapy. Different confounding factors 
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like gender, the presence of chronic kidney disease or various inflammatory triggers might have 
also influenced the results of this meta-analysis. Smoking status is another factor, which might 
have modified our results since nicotine is known to decrease plasma adiponectin levels through 
changing KATP channels in adipocytes 49. Furthermore, various changes of plasma adiponectin 
concentrations are dependent by different pharmacokinetic profiles of statins used (lipophilicity, 
metabolism, half-life, protein binding, and bioavailability, presence of active metabolites or 
excretion) 50.  
In conclusion, the meta-analysis showed a significant increase in plasma adiponectin levels 
following statin therapy. Although statins are known to increase the risk for NOD, our data 
might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin 
expression. The pleiotropic adiponectin-elevating effect of statins may also explain, at least in 
part, the putative benefits of these drugs in reducing cardiovascular risk in diabetic patients.  
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Table 1.Demographic characteristics and baseline parameters of the studies selected for analysis. 
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Year  2012 2008 2007 2012 2011 2010 2007 2005 2008 2013 2005a 2005b 2009 2010 2011a 2011b 2013a 2013b 2008 2014 2004 2007 2009 2010 2008 2004 2007 2009 2011 2009 
Location  Poland Taiwan USA Korea Egypt USA Germany Lebanon Germany Korea Korea Korea Korea Korea Korea Korea Korea Korea Korea Poland Korea Japan Japan Italy Japan USA Japan Netherlands Japan China 
Design  Randomized 
simple-blind 
parallel group trial 
Randomize
d parallel 
group trial 
Randomiz
ed, 
double-
blind, 
placebo-
controlled 
parallel 
group 
trial 
Randomiz
ed parallel 
group trial 
Randomize
d parallel 
group trial 
Multicenter 
randomized open 
label parallel 
group trial 
Two center 
randomized 
double-blind 
parallel group trial 
Randomiz
ed, 
double-
blind, 
placebo-
controlled 
parallel 
group trial 
Randomized 
parallel group 
trial 
Multicenter, 
double-blind, 
placebo-
controlled, 
factorial 
randomized trial 
Randomized, 
double-blind, 
placebo-controlled 
crossover trial 
Randomized, 
double-blind, 
placebo-
controlled 
crossover trial 
Randomized, 
single-blind, 
placebo-
controlled, 
parallel group 
trial 
Randomized, 
single-blind, 
placebo-
controlled, 
parallel group 
trial 
Randomized, 
single-blind, 
placebo-
controlled, 
crossover trial 
Randomized, 
single-blind, 
placebo-
controlled, 
parallel group 
trial 
Randomized, 
single-blind, 
placebo-
controlled, 
parallel group 
trial 
Randomized, 
single-blind, 
placebo-
controlled, 
crossover trial 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel group 
trial 
Open-label, 
parallel group 
trial 
Randomized, 
double-blind, 
placebo-
controlled 
crossover trial 
Randomized 
parallel group 
trial 
Randomized parallel 
group trial 
Randomized 
parallel group 
trial 
Randomi
zed 
parallel 
group 
trial 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel group 
trial 
Open-label, 
randomized 
parallel group 
trial 
Randomized, 
double-blind, 
placebo-
controlled, 
parallel group 
trial 
Randomi
zed 
parallel 
group 
trial 
Randomized 
parallel 
group trial 
Duration of 
trial 
 90 days 6 months 8 weeks 6 months 6 months 48 weeks 12 weeks 12 weeks 14 days 16 weeks 2 months 2 months 2 months 2 months 2 months 2 months 2 months 2 months 2 months 12 weeks 2 months 6 months 6 months 30 days 12 
months 
12 weeks 6 months 30 weeks 2 months 12 weeks 
Inclusion 
criteria 
 Patients with 
mixed 
hyperlipidemia 
(total cholesterol 
>200 mg/dL LDL-
C >130 mg/dL and 
triglycerides 
>200mg/dL) 
fasting glucose 
(100-125 mg/dL), 
glycemia at 2 
hours of OGTT 
<140 mg/dL, BMI 
25-35 kg/m2, 
postmenopausal 
state or effective 
methods of 
mechanical 
contraception 
CAD 
patients 
with stable 
angina and 
normal 
lipid 
profiles 
scheduled 
for PCI 
(balloon 
angioplasty 
and 
stenting), 
and who 
were not 
taking 
statins 
Patients 
with MS 
as defined 
using the 
criteria of 
the 
National 
Cholester
ol 
Education 
Panel 
Adult 
Treatment 
Panel III 
Patients 
who were 
20 yrs of 
age or 
older and 
had been 
maintaine
d on PD > 
3 months 
Patients 
with RA 
fulfilling 
the 1987 
American 
College of 
Rheumatol
ogy revised 
criteria, 
with 
disease 
duration<1 
year with 
no prior 
use of 
disease-
modifying 
antirheuma
tic drugs 
and/or 
systemic 
steroids 
HIV-infected 
persons with 
combined 
hyperlipidemia 
Patients with 
previous medical 
history of 
infarction, and/or 
coronary 
angiography with 
proven 
cardiovascular 
disease, and/or 
unstable angina 
pectoris, and/or 
duplex sonography 
of cervical or leg 
vessels with proven 
arteriosclerotic 
alterations, and/or 
electrocardiogram 
with ischemia, 
and/or stroke, 
and/or transient 
ischemic attack, 
and/or peripheral 
arterial occlusion, 
and/or vessel 
surgery, and/or 
hypertension 
Healthy 
volunteers 
Male volunteers 
aged between 18 
and 60 yrs, with 
BMI between 
18.5 and 30 
kg/m2, LDL-C 
concentrations< 
190 mg/dL, 
triglycerides < 
250 mg/dL and 
normal blood 
pressure (< 
140/90 mmHg) 
Female patients 
between 30 and 
70 yrs of age 
with a less than 
10-year recorded 
history of type 2 
DM and 
hypercholesterol
emia 
Patients with 
combined 
hyperlipidemia 
(total cholesterol 
200 mg/dl and 
triglycerides 
ranging from 200 
mg/dl to 800 
mg/dL) 
Hypercholesterol
emic patients 
with type 2 
diabetes (LDL 
cholesterol levels 
>100 mg/dL) 
Patients with 
hypercholesterol
emia (LDL 
cholesterol 
levels 
≥130mg/dL) 
Patients with 
hypercholesterol
emia (LDL 
cholesterol 
levels >100 
mg/dL) 
Patients with mild-
to-moderate 
hypertension 
(systolic blood 
pressure <180 and 
diastolic blood 
pressure <110mm 
Hg) 
Patients with 
hypercholesterol
emia (LDL 
cholesterol 
levels ≥100 
mg/dL and 
BMI≥23.0 
kg/m2) 
Hypercholesterol
emic patients 
(LDL cholesterol 
levels ≥130 
mg/dL) 
Hypercholesterol
emic patients 
(LDL cholesterol 
levels ≥130 
mg/dL) 
Patients with 
hypercholesterol
emia (LDL 
cholesterol 
levels ≥100 
mg/dL and BMI 
≥23.0 kg/m2) 
Patients with 
isolated 
hypercholesterole
mia, defined as 
total plasma 
cholesterol above 
200 mg/dL, LDL 
cholesterol above 
130 mg/dL, and 
triglycerides 
below 150 mg/dL 
Hypercholesterol
emic, 
hypertensive 
patients (LDL 
cholesterol levels 
≥100 mg/dL, 
systolic and 
diastolic blood 
pressure ≥140 or  
≥90 mm Hg, 
respectively)  
Patients with 
stable CAD 
(≥75% 
narrowing ≥1 
major coronary 
artery) who had 
both 
hypercholesterol
emia (180 
mg/dL≤serum 
total cholesterol 
levels < 260 
mg/dL) and 
hypertriglycerid
emia (150 
mg/dL≤serum 
triglycerides 
levels < 400 
mg/dL) 
Patients with diabetes 
and hyperlipidemia 
Patients with 
polygenic 
hypercholesterol
emia (patients, 
LDL-C > 160 
mg/dL), 
Patients 
with 
chronic 
kidney 
disease 
(stage 2 
to 4)with 
an 
estimated 
GFR <90 
mL/min 
and ≥15 
mL/min. 
Diabetic 
patients with 
no serious 
long-term 
complications 
(macroalbumin
uria, severe 
neuropathy, 
and/or 
peripheral 
vascular 
disease 
associated with 
foot ulceration 
or other lower 
extremity 
amputations) 
or were 
considered at 
higher risk to 
develop type 2 
diabetes than 
the general 
population 
Non-
hypercholesterol
emic (total 
cholesterol <220 
mg/dL); and 
non-diabetic 
(fasting glucose 
<126 mg/dL, 2 h 
post-
loadedglucose 
<200 mg/dL and 
glycosylated 
hemoglobin A1c 
(HbA1c) <6.4%) 
and without 
taking any lipid-
lowering 
medications 
Men and 
women aged 
45–75 yrs, with 
a known 
duration of type 
2 diabetes of at 
least 1 year and 
mild 
hypertriglycerid
emia (total 
cholesterol 
levels between 
4.0 and 8.0 
mmol/L and 
fasting 
triglyceride 
levels between 
1.5 and 6.0 
mmol/L) 
Patients 
with 
CAD, 
with 
serum 
LDL 
cholester
ol level 
>100 
mg/dL 
Type 2 
diabetic 
patients 
Statin form  atorvastatin atorvastatin simvastati
n 
rosuvastati
n 
atorvastati
n 
pravastatin simvastatin pravastati
n 
simvastatin pravastatin atorvastatin simvastatin simvastatin atorvastatin atorvastatin simvastatin rosuvastatin pravastatin simvastatin simvastatin simvastatin atorvastatin pitavastatin atorvastatin rosuvasta
tin 
atorvastatin pravastatin atorvastatin pravastati
n 
simvastatin 
pravastatin pravastatin rosuvasta
tin 
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Statin 
intervention 
 10 mg/day 10 mg/day 40 
mg/day 
10 mg/day 40 mg/day 40 mg/day 40 mg/day** 40 
mg/day 
40 mg/day 20 mg/day 10 mg/day 20 mg/day 20 mg/day 10 mg/day 20 mg/day 20 mg/day 10 mg/day 40 mg/day 10 mg/day 40 mg/day 20 mg/day 10 mg/day 2 mg/day 10 mg/day 2.5 
mg/day 
20 mg/day 10-20 mg/day 10 mg/day 10 
mg/day 
40 mg/day 
combination: 
atorvastatin+fenof
ibrate (267 
mg/day) 
combination: 
pravastatin+fenofi
brate (200 
mg/day) 
combination: 
simvastatin+pioglit
azone (45 
mg/day)** 
combination: 
simvastatin+ezeti
mibe (10 
mg/day) 
40 mg/day combination: 
atorvastatin+fenof
ibrate (200 
mg/day) 
combination: 
simvastatin+rami
pril (10 mg/day) 
40 mg/day 20 mg/day combination: 
atorvastatin+amlo
dipine (10 mg/day) 
40 mg/day 40 mg/day combination: 
pravastatin+vals
artan (160 
mg/day) 
20 mg/day combination: 
simvastatin+ezeti
mibe (10 
mg/day) 
combination: 
simvastatin+losar
tan (100 mg/day) 
combination: 
pitavastatin+eicosapent
aenoic acid (1800 
mg/day) 
80 mg/day 2.5 
mg/day 
40 mg/day 40 mg/day 
80 mg/day 
Participants Statin 
group 
16 30 25 35 15 37 43 19 24 28 56 50 43 42 42 45 52 48 30 23 47 16 64 18 22 34 20 73 12 23 
44 32 
19 60 43 24 25 42 43 45 53 31 21 72 72 11 
40 
Contr
ol 
group 
14 30 25 35 15 37 39 21 24 20 42 44 44 53 32 21 15 55 18 16 33 20 72 13 20 
Age (years) Statin 
group 
52.9±7.2 66.13±11.5
0 
51±12 48.9±11.7 54.8±14.7 42 (31–57) 57.3±8.4 51.6±13.0 31.9±8.8 60 (36-70) 56±1** 59±1** 58±2** 56±10 53±2** 58±2** 55±1** 56±1** 57±2** 51.9±2.7 57±2** 60±7 65±3 55.2±4.1 63.8±9.1 NS 68.2±8.3 59.7±7.6** 65±2** 58.5±1.6** 
58±9 58±2** 
51.9±9.1 44 (28–57) 59.0±8.6 34.1±11.2 60 (41-69) 56±2** 59±12 61±2** 54±1** 60±2** 52.5±3.5 60.1±7.7** 66±3** 
57±11 
Contr
ol 
group 
49.1±8.8 63.77±12.7
3 
48.5±11.3 53.7±15.4 46 (28–62) 59.5±7.8 46.3±9.7 28.6±6.6 57 (34-70) 59±1** 54±11 57±2** 56±1** 59±2** 51.1±2.6 59±8 55.2±3.8 67.0±7.9 NS 65.7±9.2 58.5±7.5** 69±2** 55.2±2.3** 
Male (%) Statin 
group 
56.25 80.0 28 45.7 20.0 91.89 37.21 52.63 100.0 0.0 41.07 60.0 39.53 50.0 52.38 44.44 42.31 60.42 46.67 61.0 42.55 63.0 52.88 44.44 50.0 55.84 65.0 60.0 83.33 39.1 
47.72 46.87 
47.37 95.0 41.86 100.0 0.0 35.71 51.16 42.22 39.62 45.16 57.0 53.0 81.81 
50.0 
Contr
ol 
group 
50.0 63.3 45.7 13.33 100.0 48.75 57.14 100.0 0.0 38.09 52.27 47.72 41.51 46.87 57.0 67.0 50.0 56.25 75.0 46.0 100.0 70.0 
BMI (kg/m2) Statin 
group 
29.5±3.6 25.86±2.51 39±7 22.9±3.1 25.8±3.1 26.4 (24.0–30.9)* 30.5±3.7 26.8±4.28 26.4±3.2 26.2±2.6 25.46±0.34** 25.5±0.4** 25.25±0.53** 24.8±3.4 25.45±0.36** 25.3±0.5** 24.00±0.43** 25.66±0.43** 25.9±0.7** 26.5±2.6 25.2±0.5** 25±2 27.3±3.9 25.2±2.7 23.1±2.5 29.5±1.3 23.0±2.3 30.0±3.8** 23.7±0.5
** 
24.5±0.6** 
24.9±3.4 27.0±0.5** 
27.8±2.6 25.9 (22.6–28.3)* 31.2±4.1 25.8±3.1 26.2±3.4 25.47±0.34** 25.48±0.48** 25.1±3.0 25.48±0.37** 25.4±0.4** 23.75±0.40** 25.50±0.46** 26.8±0.6** 26.9±2.2 30.4±4.5** 24.8±1.3
** 
24.9±3.4 
Contr
ol 
group 
28.3±2.2 25.12±2.48 22.7±3.0 25.5±3.3 25.4 (22.2–27.1)* 30.8±4.8 26.1±4.20 25.0±3.3 26.0±3.5 25.45±0.34** 24.52±0.54** 24.8±2.4 25.51±0.35** 24.9±0.5** 23.95±0.35** 25.48±0.47*** 25.7±0.6** 27.2±2.6 26±2 25.2±2.3 23.4±2.9 28.8±1.1 23.9±2.4 32.2±6.0** 24.2±1.2
** 
24.1±0.8** 
hs-CRP 
(mg/L) 
Statin 
group 
NS 0.89±1.16 3.6 (3, 
6.1) 
2.05±1.57 31.46±14.3
3 
3.5 (2.1–6.0)* NS NS NS 0.12 (0.03-1.10) 1.20 (0.65–2.20)* 1.10 (0.60–
2.90)* 
1.00 (0.40–
3.10)* 
0.95 (0.50–
3.10)* 
1.05 (0.80–2.40)* 1.10 (0.40–
2.70)* 
0.60 (0.40–
1.27)* 
0.85 (0.50–
1.60)* 
0.64 (0.27–2.91) 3.4±0.5 0.85(0.30–2.70)* −1.20 ± 0.4$ NS NS 0.89±0.8
9 
0.32±0.05 1.4 (0.8–2.3)* NS 405±309
** 
4.3±1.0** 
1.00 (0.45–
2.00)* 
1.05 (0.40–2.35) 
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NS 2.7 (1.5–4.5)* NS NS 0.11 (0.03-1.43 0.80 (0.53–2.03)* 1.60 (0.60–3.50* 1.45 (0.60–
2.10)* 
1.00 (0.53–
2.30)* 
1.40 (0.90–2.40)* 0.80 (0.44–
1.75)* 
0.70 (0.40–
1.35)* 
1.00 (0.63–
1.80)* 
0.73 (0.44–1.39) 3.7±0.7 0.85(0.50–2.00)* NS 389±162
** 
1.00 (0.65–
2.00)* 
Contr
ol 
group 
NS 0.71±0.88 5.3 (2.4, 
6.6) 
1.90±1.33 33.06±14.1
3 
2.4 (1.2–3.9)* NS NS NS 0.10 (0.03-0.63) 1.20 (0.70–2.35)* 1.30 (0.60–
2.80)* 
1.00 (0.70–
2.20)* 
1.00 (0.65–
2.30)* 
1.30 (0.80–2.50)* 1.00 (0.70–
2.10)* 
0.60 (0.30–
1.20)* 
1.10 (0.50–
1.78)* 
0.95 (0.46–2.10) 3.5±0.6 0.85(0.50–2.30)* −1.27 ± 0.3$ NS 0.88±0.8
4 
0.30±0.05 1.1 (0.5–2.0)* NS 579±165
** 
3.8±1.4** 
Total 
cholesterol(mg
/dL) 
Statin 
group 
257.9±22.2 195.13±36.
32 
NS 190.3±25.
47 
228.13±11.
75 
260 (249–289)* 221.18±42.46 234±51.7 NS 243.18±27.02 243±7** 229±6** 260±5** 238±34 219±6** 258±5** 246±3** 233±6** 246±3** 258±16 247±5** NS 254±24 279±47 228.5±47
.6 
199.8±7.0 188±16 228.51±35.51** 193±17*
* 
185.28±7.72
** 
245±37 256±7** 
265.6±28.8 269 (248.5–316)* 218.86±48.63 NS 239.22±19.3 234±6** 227±6** 254±5** 242±31 227±5** 263±4** 241±4** 234±5** 264±6** 256±15 242±4** 251±45 231.98±34.35** 202±10*
* 
253±41 
Contr
ol 
group 
231.1±40.7 193.57±41.
31 
NS 190.68±46
.32 
224.66±31.
12 
281 (252–325)* 216.16±38.21 229.8±48.
9 
NS 243.18±34.74 240±6** 223±7** 267±5** 240±32 211±5** 268±5** 248±4** 229±6** 267±6** 246±14 238±5** NS 229±37 280±29 205.6±28
.1 
211.9±7.0 183±21 233.144±31.26*
* 
179±9** 173.7±7.72*
* 
LDL-C 
(mg/dL) 
Statin 
group 
152.1±17.9 128.67±28.
80 
NS 117.73±28
.56 
142.66±24.
33 
160 (145–179)* 138.96±38.98 159.6±43.
9 
NS 154.4±15.44 134±7** 135±6** 178±5** 156±31 132±6** 176±5** 166±4** 151±5** 162±3** 186±13 160±5** 136±25 169±21 188±17 130.3±24
.3 
120.4±5.9 122±15 NS 124±16*
* 
100.36±3.86
** 
159±33  174±7** 
165.3±26.4 156.5 (139–179)* 142.05±42.46 NS 146.68±15.44 130±7** 134±5** 170±5** 155±27 137±5** 177±5** 165±3** 148±4** 181±7** 184±11 154±5** 156±31 NS 127±8** 
169 ±38 
Contr
ol 
group 
152.7±41.6 123.93±37.
78 
NS 115.8±37.
05 
142.33±24.
41 
148 (132–176)* 135.1±36.28 149.7±43.
8 
NS 158.26±27.02 128±6** 134±7** 177±6** 154±29 124±5** 177±6** 166±4** 146±5** 179±6** 178±12 149±5** 130±23 128±32 187±7 128.3±16
.2 
127.0±5.6 118±20 NS 93±5** 96.5±7.72** 
HDL-C 
(mg/dL) 
Statin 
group 
43.7±11.1 40.97±8.16 NS 52.88±15.
05 
41.60±10.8
5 
35 (32–41)* 55.2±15.82 44.1±14.1 NS 50.18±11.58 46±1** 46±2** 51±2** 51±12 48±2** 52±2** 53±2** 53±1** 54±1** 46±4 53±2** 43±8 48±14 62±12 55.9±14.
5 
58.8±2.3 46±10 40.53±1.158** 45.7±3.2
** 
40.53±0.38*
* 
54±13 52±2** 
43.0±10.1 35 (30–39)* 55.58±17.37 NS 54.04±3.86 44±1** 47±1** 54±2** 51±12 51±2** 56±2** 51±1** 51±1** 54±2** 46±4 51±2** 46±17 40.14±1.15** 51.0±4.2
** 
52±11 
Contr
ol 
group 
44.1±10.7 38.77±8.86 NS 52.88±18.
14 
44.06±9.12 34 (30–39)* 54.42±15.82 47.8±13.5 NS 54.04±7.72 46±1** 47±2** 55±2** 50±11 47±2** 54±1** 54±1** 52±2** 57±2** 47±4 52±2** 44±6 43±15 61±11 54.9±10.
6 
61.9±3.3 49±10 40.53±1.15** 42.5±3.0
** 
42.46±3.86*
* 
Triglycerides 
(mg/dL) 
Statin 
group 
240.1±14.6 163.57±12
3.48 
NS 95.58 
(71.68–
152.22) 
126.93±31.
97 
307 (225–399)* 144.25±145.14 146.6±56.
9 
NS 141.6 (70.8-
300.9) 
301±23** 236±25** 143±13** 152±69 201±16** 142±13** 136±8** 151±9** 131±12** 122±12 172±12** 5.4±0.3$ 198±57 103±24 177.1±73
.2 
114.3±15.0 122 (92–162)* 235.41±9.73** 166±44*
* 
221.25±26.5
5** 
157±71 147±18** 
248.1±39.6 355 (252.5–
468.5)* 
128.32±52.21 NS 141.6 (44.25-
300.9) 
337±24** 231±17** 162±9** 179±98 196±15** 155±14** 136±8** 164±10** 149±16** 126±11 179±13** 248±61 260.19±12.39** 112±20*
* 
164±88 
Contr
ol 
group 
226.6±35.5 168.80±10
7.70 
NS 107.08 
(84.07–
167.26) 
137.33±47.
31 
375 (262–457)* 132.75±64.6 168.5±10
0.7 
NS 141.6 (8.85-
345.15) 
322±19** 213±18** 147±12** 172±89 203±18** 144±12** 138±10** 158±12** 146±15** 120±12 186±16** 5.3±0.2$ 258±72 102±19 161.2±35
.3 
110.2±13.0 101 (85–129)* 249.57±11.5** 174±26*
* 
177.0±44.25
** 
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Adiponectin 
(µg/mL) 
Statin 
group 
17.5±2.7 8.66±3.79 7.7±2.1 21.0±6.1 19.21±2.10 4.5 (3–7)* 15.49±12.66 7.30±4.79 13.28±5.29 3.22±1.27 3.5 (2.6–5.0)* 3.8 (2.7–5.2)* 5.8±0.8** 2.8±2.4 3.3±0.3** 5.7±0.7** 2.05 (1.37–
3.75)* 
2.97 (2.09–
4.80)* 
6.4±1.0** 5.3±1.2 4.5 (3.4–7.0)* 1.4±0.5$ 3.29±0.51 5.5 (4–8)* 9.7±5.3 21.7±2.3 5.2 (4.0–6.5)* 7.69±0.46** 3.28±0.1
1** 
4.8±0.6** 
3.1±2.4 6.0±1.0** 
16.2±2.7 4 (3–6)* 11.68±9.96 13.63±4.88 3.19±1.28 3.4 (2.3–4.7)* 3.8 (2.5–6.2)* 5.6±0.6** 3.4±2.5 3.2±0.3** 6.8±0.7** 2.00 (1.22–
4.12)* 
2.81 (1.96–
5.03)* 
6.2±0.8** 6.0±1.0 4.6 (3.3–6.4)* 3.24±0.41 8.20±0.58** 2.95±0.5
6** 
3.2±2.4 
Contr
ol 
group 
17.8±3.4 8.80±3.74 7.3±1.9 21.3±9.9 19.81±1.95 4 (3–6)* 13.96±8.16 7.36±3.59 13.17±5.97 3.76±2.31 3.2 (2.5–5.1)* 3.8 (2.6–6.7)* 6.2±0.7** 3.3±2.0 3.2±0.3** 6.8±0.8** 2.05 (1.32–
6.07)* 
2.96 (1.92–
5.45)* 
6.6±1.0** 5.7±1.1 4.2 (3.5–6.2)* 1.5±0.6$ 3.03±0.57 NS 8.9±3.9 25.2±3.5 5.8 (4.1–6.7)* 7.44±0.42** 3.51±0.4
1** 
4.5±0.4** 
Glucose 
(mg/dL) 
Statin 
group 
107.6±6.0 NS 114±55 93.06±8.8
2 
NS NS 100.8±11.16 92.8±15.1 NS 144.0±37.8 92±3** 122±5** 97±2** 106±18 104±2** 85±2** 97±1** 102±1** 89±9** 95±4 82±2** 118±30 NS 84±11 97.1±10.
9 
NS 92±11 189.0±54.0** 145±12*
* 
NS 
108±21 86±3** 
103.0±8.0 NS 102.6±11.88 NS 140.4±25.2 89±3** 128±6** 99±3** 113±24 106±2** 91±3** 98±1** 105±2** 91±4** 96±4 82±2** NS 190.8±52.2** 139±9** 
109±22 
Contr
ol 
group 
110.3±6.5 NS 109±35 92.34±26.
64 
NS NS 101.34±9.72 89.5±9.2 NS 151.2±39.6 91±4** 121±5** 94±3** 103±17 104±3** 94±3** 96±2** 103±2** 95±4** 95±5 83±2** 118±31 NS 85±13 98.2±18.
6 
NS 91±8 189.0±64.8** 131±20*
* 
NS 
SBP (mmHg) Statin 
group 
NS NS NS 136.6±19.
7 
NS NS NS NS NS 126.8±11.8 NS 134±2** NS NS 154±1** NS NS 138±2** NS NS 145±2** NS NS 124±12 126.7±9.
3 
NS NS 146±17** NS NS 
NS NS 
NS NS NS NS 125.1±21.8 NS 135±2** NS NS 157±1** NS NS 134±2** NS NS 147±3** NS 145±17** NS 
NS 
Contr
ol 
group 
NS NS NS 136.8±17.
2 
NS NS NS NS NS 129.8±7.7 NS 131±2** NS NS 156±2** NS NS 138±2** NS NS 145±2** NS NS 125±12 128.3±8.
1 
NS NS 144±19** NS NS 
DBP (mmHg) Statin 
group 
NS NS NS 81.1±7.7 NS NS NS NS NS 76.4±7.1 NS 80±1** NS NS 94±1** NS NS 85±2** NS NS 90±1** NS NS 74±7 76.7±8.2 NS NS 86±10** NS NS 
NS NS 
NS NS NS NS 76.3±6.8 NS 80±1** NS NS 96±1** NS NS 82±2** NS NS 91±1** NS 85±9** NS 
NS 
Contr
ol 
group 
NS NS NS 80.9±10.5 NS NS NS NS NS 81.2±6.8 NS 78±1** NS NS 95±1** NS NS 83±2** NS NS 89±1** NS NS 76±10 80.4±5.4 NS NS 85±9** NS NS 
Values are expressed as mean ± SD or median (range);* median (25th–75th percentiles); ** mean ± SEM; $values of adiponectin levels, CRP levels and triglycerides levels are log-transformed. 
BMI: body mass index; NS: not stated; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; SBP: systolic blood pressure; DBP: diastolic blood pressure; hs-CRP: high-sensitivity C-reactive 
protein; BMI: body mass index; OGTT: oral glucose tolerance test; CAD: coronary artery disease; PCI: percutaneous coronary intervention; MS: metabolic syndrome; PD: peritoneal dialysis; RA: rheumatoid arthritis; DM: diabetes 
mellitus; GFR:glomerular filtration rate. 
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Table 2. Assessment of risk of bias in the included studies using Cochrane criteria. 
Study Ref Sequence generation Allocation concealment Blinding of participants and personnel Blinding of outcome assessment Incomplete outcome data Selective outcome reporting Other potential threats to validity 
Buldak et al. 2012 51 U U L U L L L 
Chan et al. 2008 52 U U L U L L L 
Devaraj et al. 2007 53 U U L U L L L 
Doh et al. 2012 54 L L L U L L L 
El-Barbery et al. 2011 55 U U L L L L L 
Fichtenbaum et al. 2010 56 H H H U L L L 
Forst et al. 2007 57 U U L L L L L 
Gannage-Yaredet et al. 2005 58 U U L U L L L 
Gouni-Berthold et al. 2008 59 U U L U L L L 
Kim et al. 2013 60 U U L U L L L 
Koh et al. 2005a 61 U U L L L L L 
Koh et al. 2005b 62 U U L L L L L 
Koh et al. 2009 63 U U L L L L L 
Koh et al. 2010 64 L L L U L L L 
Koh et al. 2011a 65 U U L L L L L 
Koh et al. 2011b 66 U U L U L L L 
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Koh et al. 2013a 67 L L L U L L L 
Koh et al. 2013b 68 U U L L L L L 
Koh et al. 2008 69 U U L L L L L 
Krysiak et al. 2014 70 H H H L L L L 
Kwang et al. 2004 71 U U L L L L L 
Nakamura et al. 2007 72 U U L U L L L 
Nomura et al. 2009 73 U U L U L L L 
Roberto et al. 2010 74 L L L L L L L 
Sawara et al. 2008 75 U U L L L L L 
Shetty et al. 2004 76 U U L U L L L 
Sugiyama et al. 2007 77 L L L U L L L 
van Hoek et al. 2009 78 U U L U L L L 
Yokoyama et al. 2011 79 U U L U L L L 
Hu et al. 2009 80 U U L L L L L 
 
L: low risk of bias; H: high risk of bias; U: unclear risk of bias. 
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FIGURE LEGENDS:  
Fig. 1. Flow chart of the number of studies identified and included into the meta-analysis.   
Fig. 2. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of statin therapy on plasma adiponectin concentrations.  
Fig. 3. Results of sensitivity analysis based on leave-one-out approach. 
Fig. 4. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of statin therapy on plasma adiponectin concentrations in trials with different 
types of statins. 
Fig. 5. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of statin therapy on plasma adiponectin concentrations in trials lasting <12 
weeks and ≥12 weeks. 
Fig. 6. Forest plot displaying weighted mean difference and 95% confidence intervals for 
the impact of statin therapy on plasma adiponectin concentrations in trials administering 
statins as monotherapy or in combination with other agents. 
Fig. 7. Meta-regression bubble plots of the association between mean changes in plasma 
adiponectin concentrations with changes in plasma LDL-C concentrations (upper plot) and 
duration of treatment (lower plot). The size of each circle is inversely proportional to the size 
of the study. 
Fig. 8. Funnel plot detailing publication bias in the studies reporting the impact of statin 
therapy on plasma adiponectin concentrations. Open diamond represents observed effect size; 
closed diamond represents imputed effect size. 
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HIGHLIGHTS: 
 
• The effect of statin therapy on plasma adiponectin levels has not been conclusively 
studied. 
• The analysis shows a significant increase in plasma adiponectin levels after statin 
therapy (weighted mean difference (WMD): +0.57 µg/mL). 
• The meta-analysis confirmed that statins may have an important impact on the 
adiponectin levels.  
• The pleiotropic adiponectin-elevating effect of statins might explain the benefits of 
statins in reducing the cardiovascular risk.  
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